1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biontech, Instadeep Develop and Successfully Test Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

01/12/2022 | 06:06am EDT

BioNTech SE and Tunisian InstaDeep Ltd announced on Tuesday the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2.

The Early Warning System (EWS) developed in collaboration by BioNTech and InstaDeep is based on artificial intelligence (AI) calculated immune escape and fitness metrics.

The new method combines structural modeling of the viral Spike protein and AI algorithms to quickly flag potential high-risk variants entered into SARS-CoV-2 sequence data repositories within less than a day based on metrics scoring their fitness as well as their immune escape properties, reads a BioNTech press release issued Tuesday.

The companies validated these predictions using experimental data generated in-house and publicly available data.

During the trial period, the system has identified >90% of the World Health Organization (WHO)-designated variants (Variants of Concern, VOC; Variants of Interest, VOI; Variants Under Monitoring,VUM) on average two months in advance. WHO-designated variants Alpha, Beta, Gamma, Theta, Eta and Omicron were detected by the EWS in the same week its sequence was first uploaded.

The Omicron variant was ranked as a high-risk variant the same day its sequence became available.

The IHU variant observed in France has also been evaluated by the EWS, which highlighted immune escape properties that are relatively similar to Omicron but with significantly lower fitness, making it less of a concern given current data.

The results from the study underline that the EWS is capable of evaluating new variants in minutes and risk monitoring variant lineages nearly in real-time. It is also fully scalable as new variant data becomes available.

"With the advanced computational methods we have been developing over the past months we can analyse sequence information of the Spike protein and rank new variants according to their predicted immune escape and ACE2 binding score," said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech.

"Early flagging of potential high-risk variants could be an effective tool to alert researchers, vaccine developers, health authorities and policy makers, thereby providing more time to respond to new variants of concern," he added.

For his part, Co-Founder and CEO of InstaDeep Karim Beguir said that more than 10,000 novel variant sequences are currently discovered every week and human experts simply cannot cope with complex data at this scale. We've addressed this challenge by deploying the powerful AI capabilities of InstaDeep's DeepChain platform combined with BioNTech's SARS-CoV-2 know-how and technology.

"For the first time, high-risk variants could be detected on the spot, potentially saving months of precious time. We are happy to make our research work publicly available and, most importantly, look forward to its continued real-world impact," he added.

Copyright Tunis Afrique Presse. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about BIONTECH SE
05/17Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US
MT
05/17UBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating
MT
05/17Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children
MT
05/17Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi..
MT
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/17PRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech..
DJ
05/16European ADRs Move Higher in Monday Trading
MT
05/16WALL STREET STOCK EXCHANGE : China added to the list of investors' fears
05/16Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European C..
AQ
05/15Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 795 M 17 691 M 17 691 M
Net income 2022 8 929 M 9 404 M 9 404 M
Net cash 2022 16 669 M 17 557 M 17 557 M
P/E ratio 2022 4,40x
Yield 2022 -
Capitalization 36 869 M 38 834 M 38 834 M
EV / Sales 2022 1,20x
EV / Sales 2023 0,98x
Nbr of Employees 3 082
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 151,71 €
Average target price 225,86 €
Spread / Average Target 48,9%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-38.01%38 834
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-16.20%42 682
GENMAB A/S-20.15%19 472